IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v2y2018i4d10.1007_s41669-018-0079-y.html
   My bibliography  Save this article

Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary

Author

Listed:
  • Erik Nord

    (Norwegian Institute of Public Health)

  • Christoffer Lamøy

    (University of Oslo)

Abstract

No abstract is available for this item.

Suggested Citation

  • Erik Nord & Christoffer Lamøy, 2018. "Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary," PharmacoEconomics - Open, Springer, vol. 2(4), pages 357-358, December.
    • Handle: RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-018-0079-y
    DOI: 10.1007/s41669-018-0079-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-018-0079-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-018-0079-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. David Meltzer, 1997. "Accounting for Future Costs in Medical Cost-Effectiveness Analysis," NBER Working Papers 5946, National Bureau of Economic Research, Inc.
    2. John A. Nyman, 2006. "More on survival consumption costs in cost‐utility analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 319-322, March.
    3. John A. Nyman, 2004. "Should the consumption of survivors be included as a cost in cost–utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 417-427, May.
    4. Jeffrey R. J. Richardson & Jan Abel Olsen, 2006. "In defence of societal sovereignty: a comment on Nyman ‘the inclusion of survivor consumption in CUA’," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 311-313, March.
    5. Afschin Gandjour, 2006. "Consumption costs and earnings during added years of life ‐ a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 315-317, March.
    6. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
    7. Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer, 2019. "Future Costs in Cost-Effectiveness Analyses: Past, Present, Future," PharmacoEconomics, Springer, vol. 37(2), pages 119-130, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bengt Liljas & Göran S. Karlsson & Nils‐Olov Stålhammar, 2008. "On future non‐medical costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 17(5), pages 579-591, May.
    2. John A. Nyman, 2011. "Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 56-67, January.
    3. Bengt Liljas, 2011. "Welfare, QALYs, and costs – a comment," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 68-72, January.
    4. Douglas Lundin & Joakim Ramsberg, 2008. "On survival consumption costs – a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 293-297, February.
    5. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    6. Charles Christian Adarkwah & Amirhossein Sadoghi & Afschin Gandjour, 2016. "Should Cost‐Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 249-256, February.
    7. Klas Kellerborg & Werner Brouwer & Matthijs Versteegh & Bram Wouterse & Pieter van Baal, 2021. "Distributional consequences of including survivor costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2606-2613, September.
    8. Dieter Tscheulin & Florian Drevs, 2010. "The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 141-150, April.
    9. Kellerborg, Klas & Wouterse, Bram & Brouwer, Werner & van Baal, Pieter, 2021. "Estimating the costs of non-medical consumption in life-years gained for economic evaluations," Social Science & Medicine, Elsevier, vol. 289(C).
    10. Pieter H. M. van Baal & Talitha L. Feenstra & Rudolf T. Hoogenveen & G. Ardine de Wit & Werner B. F. Brouwer, 2007. "Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio," Health Economics, John Wiley & Sons, Ltd., vol. 16(4), pages 421-433, April.
    11. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    12. Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer, 2019. "Future Costs in Cost-Effectiveness Analyses: Past, Present, Future," PharmacoEconomics, Springer, vol. 37(2), pages 119-130, February.
    13. Bengt Liljas, 2010. "On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 5-13, February.
    14. Richardson, Jeff & McKie, John, 2007. "Economic evaluation of services for a National Health Scheme: The case for a fairness-based framework," Journal of Health Economics, Elsevier, vol. 26(4), pages 785-799, July.
    15. Pieter H. M. van Baal & Talitha L. Feenstra & Johan J. Polder & Rudolf T. Hoogenveen & Werner B. F. Brouwer, 2011. "Economic evaluation and the postponement of health care costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(4), pages 432-445, April.
    16. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
    17. Afschin Gandjour & Dirk Müller, 2014. "Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 471-476, October.
    18. Liqun Liu & Andrew J. Rettenmaier & Thomas R. Saving, 2008. "Longevity bias in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 17(4), pages 523-534, April.
    19. Hamraz Mokri & Ingelin Kvamme & Linda Vries & Matthijs Versteegh & Pieter Baal, 2023. "Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 701-715, July.
    20. Kristian Bolin, 2012. "Economic Evaluation of Smoking-Cessation Therapies," PharmacoEconomics, Springer, vol. 30(7), pages 551-564, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:2:y:2018:i:4:d:10.1007_s41669-018-0079-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.